AIM ImmunoTech spent the first half of 2026 doing two things at once: finishing enrollment in the pivotal-adjacent DURIPANC Phase 2 trial of its lead drug Ampligen in metastatic pancreatic cancer, and rebuilding a balance sheet that was technically insolvent four months earlier. Both landed. As of June 18, 2026, the final DURIPANC subject had received its first dose, completing the trial's enrollment, and the company carried $9.9 million of cash with positive stockholders' equity of $7.7 million at June 30, 2026 - a swing from the negative $9.8 million of equity and $3.0 million of cash it held at year-end 2025.
The quarter's headline loss per share looks better and means less. GAAP net loss for Q2 2026 was $(3.8) million, or $(0.43) per diluted share, versus $(2.8) million, or $(3.68) per share, a year earlier. The per-share improvement is a dilution artifact, not an operating one: the aggregate loss widened by roughly 35%, and the weighted-average share count grew about 22-fold to 17.1 million as equity was issued to fund the turnaround. Investors are not buying a smaller loss; they are buying the inflection this financing bought.
The market has priced the rest of the story. At $0.255, the shares trade around book value and below the roughly $0.34 of cash each outstanding share is backed by - against a $9.9 million cash pile and only about $3.6 million of debt, the enterprise value of the entire Ampligen clinical franchise is roughly $1 million to $1.5 million. That is the market assigning essentially zero value to a Phase 2 readout due in early 2027. The next two reports - the topline clinical benefit data in Q1 2027 and overall survival in Q3 2027 - decide whether that discount is an opportunity or the correct price.